Loading
A phase 2/3 trial of Alpelisib in childhood cancers, run by Novartis Pharmaceuticals, now recruiting.
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. is a phase 2/3 interventional study registered as NCT05948943 by Novartis Pharmaceuticals, with 232 participants planned, started 2023-11-24 and due to reach its primary completion in 2028-05-31. Interventions recorded: Alpelisib and Placebo.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.